The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Colon cancer is one of the most lethal malignancies, and colorectal cancer ranks the fifth
leading cause of tumor-related mortality in China. FOLFOX is the recommended adjuvant/
neoadjuvant treatment for advanced colon cancer. JS001, as the first Chinese produced
anti-PD-1 monoclonal antibody, has been approved by CFDA. This study aims to assess the
safety and efficacy of JS001 in combination with FOLFOX as adjuvant/neoadjuvant treatment for
patients with locally advanced colon cancer.